两种形式欧米伽-3补充剂治疗干眼病的随机双盲安慰剂对照临床试验
这项单中心随机双盲安慰剂对照试验将60例轻中度干眼病患者按1:1:1分为安慰剂(橄榄油)、磷虾油和鱼油三组,干预90天。磷虾油组和鱼油组的泪液渗透压较基线均显著降低,仅磷虾油组眼表疾病指数(OSDI)评分较安慰剂组显著改善;两种欧米伽-3脂肪酸(ω-3 EFA)在泪膜破裂时间和球结膜充血方面均相对安慰剂有改善。
要点
- 磷虾油和鱼油均使第90天泪液渗透压较基线显著降低,安慰剂组无此变化。
- 仅磷虾油组OSDI评分较安慰剂组显著降低(-18.6±2.4 vs -10.5±3.3;P=0.02)。
- 磷虾油组基础泪液白介素17A较安慰剂组显著降低(-27.1±10.9 vs 46.5±30.4 pg/ml;P=0.02)。
核心结论
- 每日中等剂量长链ω-3 EFA持续3个月可使干眼病患者泪液渗透压降低、泪膜稳定性增加。
- 以磷脂形式为主的磷虾油可能带来额外治疗获益,包括干眼症状改善和基础泪液白介素17A水平降低。
研究设计与样本
- 随机、双盲、安慰剂对照临床试验,在单个中心开展,60例轻中度干眼病患者按1:1:1随机分为安慰剂(橄榄油)、磷虾油、鱼油三组。
- 干预分别为橄榄油1500 mg/天、磷虾油(二十碳五烯酸[EPA] 945 mg/天+二十二碳六烯酸[DHA] 510 mg/天)、鱼油(EPA 1000 mg/天+DHA 500 mg/天),持续90天,每月随访一次。
- 共54例完成研究。
主要发现
- 第90天泪液渗透压较基线变化:磷虾油组-18.6±4.5 mOsmol/l(n=18;P<0.001),鱼油组-19.8±3.9 mOsmol/l(n=19;P<0.001),安慰剂组-1.5±4.4 mOsmol/l(n=17)。
- 第90天OSDI评分较基线变化:磷虾油组-18.6±2.4 vs 安慰剂组-10.5±3.3(P=0.02)。
- 第90天基础泪液白介素17A水平变化:磷虾油组-27.1±10.9 vs 安慰剂组46.5±30.4 pg/ml(P=0.02)。
- 第90天两种ω-3 EFA在泪膜破裂时间和球结膜充血方面均相对安慰剂有改善。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the efficacy of 2 forms of oral long-chain omega-3 (ω-3) essential fatty acid (EFA) supplements, phospholipid (krill oil) and triacylglyceride (fish oil), for treating dry eye disease (DED). DESIGN: Randomized, double-masked, placebo-controlled clinical trial. PARTICIPANTS: This study was conducted at a single site and involved 60 participants with mild to moderate DED who were randomized (1:1:1) to 1 of 3 groups: placebo (olive oil), krill oil, or fish oil supplements. METHODS: Participants received 1 of the 3 interventions: placebo (olive oil 1500 mg/day), krill oil (945 mg/day eicosapentaenoic acid [EPA], + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days, with monthly study visits. MAIN OUTCOME MEASURES: Primary outcome measures were mean change in (1) tear osmolarity and (2) DED symptoms (Ocular Surface Disease Index [OSDI] score) between days 1 and 90. Secondary outcomes included mean change in key clinical signs (tear stability, tear production, ocular surface staining, bulbar and limbal redness, tear volume, anterior blepharitis, meibomian gland capping) and tear inflammatory cytokine levels. RESULTS: In total, 54 participants completed the study. At day 90, tear osmolarity was reduced from baseline with both krill oil (mean ± standard error of the mean: -18.6±4.5 mOsmol/l; n = 18; P < 0.001) and fish oil (-19.8±3.9 mOsmol/l; n = 19; P < 0.001) supplements, compared with placebo (-1.5±4.4 mOsmol/l; n = 17). OSDI score was significantly reduced at day 90 relative to baseline in the krill oil group only, compared with placebo (-18.6±2.4 vs. -10.5±3.3; P = 0.02). At day 90, there were also relative improvements in tear breakup time and ocular bulbar redness, compared with placebo, for both forms of ω-3 EFAs. Basal tear levels of the proinflammatory cytokine interleukin 17A were significantly reduced in the krill oil group, compared with placebo, at day 90 (-27.1±10.9 vs. 46.5±30.4 pg/ml; P = 0.02). CONCLUSIONS: A moderate daily dose of both forms of long-chain ω-3 EFAs, for 3 months, resulted in reduced tear osmolarity and increased tear stability in people with DED. Omega-3 EFAs in a predominantly phospholipid form (krill oil) may confer additional therapeutic benefit, with improvements in DED symptoms and lower basal tear levels of interleukin 17A, relative to placebo.
引用
- Deinema LA, Vingrys AJ, Wong CY, et al. A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease. Ophthalmology. 2016. PMID: 27817918. doi:10.1016/j.ophtha.2016.09.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。